1
Assink, M.D., Kiewiet, J.P., Rozenbaum, M.H., van den Berg, P.B., Hak, E., Buskens, E.J., Wilschut, J.C., Kroes, A.C., Postma, M.J.
Veröffentlicht in: Assink , M D , Kiewiet , J P , Rozenbaum , M H , van den Berg , P B , Hak , E , Buskens , E J , Wilschut , J C , Kroes , A C & Postma , M J 2009 , ' Excess drug prescriptions during influenza and RSV seasons in the Netherlands : Potential implications for extended influenza vaccination ' , Vaccine , vol. 27 , no. 7 , pp. 1119-1126 . https://doi.org/10.1016/j.vaccine.2008.11.070;
2009
Veröffentlicht in: Assink , M D , Kiewiet , J P , Rozenbaum , M H , van den Berg , P B , Hak , E , Buskens , E J , Wilschut , J C , Kroes , A C & Postma , M J 2009 , ' Excess drug prescriptions during influenza and RSV seasons in the Netherlands : Potential implications for extended influenza vaccination ' , Vaccine , vol. 27 , no. 7 , pp. 1119-1126 . https://doi.org/10.1016/j.vaccine.2008.11.070;
2009
2
Rozenbaum, M.H., Mangen, M.J.J., Giaquinto, C., Wilschut, J.C., Hak, E., Postma, M.J.
Veröffentlicht in: Rozenbaum , M H , Mangen , M J J , Giaquinto , C , Wilschut , J C , Hak , E & Postma , M J 2011 , ' Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model ' , BMC Public Health , vol. 11 , 462 . https://doi.org/10.1186/1471-2458-11-462;
2011
Veröffentlicht in: Rozenbaum , M H , Mangen , M J J , Giaquinto , C , Wilschut , J C , Hak , E & Postma , M J 2011 , ' Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model ' , BMC Public Health , vol. 11 , 462 . https://doi.org/10.1186/1471-2458-11-462;
2011
3
Bos, J.M., Rietveld, E., Moll, HA, Steyerberg, E.W., Luytjes, W., Wilschut, J.C., de Groot, R., Postma, M.J.
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
4
Khayat M, Al, Eijsink, J., Postma, M., Wilschut, J.C., van Hulst, M.
Veröffentlicht in: Value in Health ; volume 22, page S651 ; ISSN 1098-3015;
2019
Veröffentlicht in: Value in Health ; volume 22, page S651 ; ISSN 1098-3015;
2019
5
Eijsink, J.F.H., Al Khayat, M.N.M.T., Boersma, C., ter Horst, P.G.J., Wilschut, J.C., Postma, M.
Veröffentlicht in: Value in Health ; volume 23, page S554 ; ISSN 1098-3015;
2020
Veröffentlicht in: Value in Health ; volume 23, page S554 ; ISSN 1098-3015;
2020